financetom
Business
financetom
/
Business
/
BRIEF-Silo Pharma Set To Acquire Exclusive Licensing For Alzheimer's Disease Therapeutic From Columbia University
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Silo Pharma Set To Acquire Exclusive Licensing For Alzheimer's Disease Therapeutic From Columbia University
Apr 10, 2024 5:50 AM

April 10 (Reuters) - Silo Pharma Inc ( SILO ):

* SILO PHARMA SET TO ACQUIRE EXCLUSIVE LICENSING FOR

PROMISING

ALZHEIMER'S DISEASE THERAPEUTIC

* SILO PHARMA INC ( SILO ) - COMPANY EXPECTS TO FINALIZE AND ENTER

INTO

EXCLUSIVE LICENSE AGREEMENT IN FIRST HALF OF 2024

* SILO PHARMA INC ( SILO ) - BELIEVES THAT SPC-14 SHOULD BE ELIGIBLE

FOR

DEVELOPMENT UNDER FDA'S 505(B)(2) REGULATORY PATHWAY

* SILO PHARMA INC ( SILO ) - UNDER TERMS, SILO WILL BE GRANTED AN

EXCLUSIVE

LICENSE TO FURTHER DEVELOP, MANUFACTURE, AND COMMERCIALIZE

SPC-14 WORLDWIDE

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved